Jonathan Goldman, MD
Medical Oncologist
Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Photodynamic Therapy Targeted Therapy
Stanford University
Medical School
UCSF
Residency
UCLA Medical Center
Fellowship
American Board of Internal Medicine - Oncology
Ronald Reagan UCLA Medical Center
Languages: English/Spanish
(310) 825-9111
757 Westwood Plaza
Read MoreEffect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
Falchook, G. S.,Zhou, X.,Venkatakrishnan, K.,Kurzrock, R.,Mahalingam, D.,Goldman, J. W.,Jung, J.,Ullmann, C. D.,Milch, C.,Rosen, L. S.,Sarantopoulos, J.; Drugs R D. 2015 Dec 23.
See more >>Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
Bendell, J. C.,Rosen, L. S.,Mayer, R. J.,Goldman, J. W.,Infante, J. R.,Benedetti, F.,Lin, D.,Mizuguchi, H.,Zergebel, C.,Patel, M. R.; Cancer Chemother. Pharmacol.. 2015 Nov 22.
See more >>Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
Bendell, J. C.,Rosen, L. S.,Mayer, R. J.,Goldman, J. W.,Infante, J. R.,Benedetti, F.,Lin, D.,Mizuguchi, H.,Zergebel, C.,Patel, M. R.; Cancer Chemother. Pharmacol.. 2015 Sep 16.
See more >>